Last updated: February 28, 2026
What is CETROTIDE?
CETROTIDE (cetrorelix acetate) is an injectable gonadotropin-releasing hormone (GnRH) antagonist. It is used in controlled ovarian stimulation protocols to prevent premature luteinizing hormone (LH) surges during assisted reproductive technologies (ART), such as in vitro fertilization (IVF). Approved in multiple jurisdictions, CETROTIDE's patent protections remain key factors shaping its market dynamics and formulation strategies.
What are the primary excipient components in CETROTIDE formulations?
The formulation of CETROTIDE typically involves the following excipients:
- Lactic acid or hydrochloric acid: Adjusts pH for stability.
- Sodium chloride: Maintains isotonicity.
- Water for injection: Solvent.
Manufacturers also include stabilizers like polyethylene glycol (PEG) or aromatic acids to enhance peptide stability. The precise excipient composition imparts stability, ensures bioavailability, and prolongs shelf life.
How does excipient choice impact CETROTIDE’s stability and administration?
Excipients influence storage conditions, injection comfort, and shelf life:
- pH adjustments with acids or buffers ensure peptide stability. CETROTIDE formulations maintain a pH between 4.2 and 4.5.
- Isotonic agents like sodium chloride prevent tissue irritation upon injection.
- Buffer systems prevent peptide aggregation, which can reduce efficacy.
Stability data indicate that CETROTIDE formulations remain stable for at least 24 months at controlled room temperature, contingent on proper excipient balance.
What are the opportunities for excipient innovation in CETROTIDE development?
Potential areas include:
- Bioavailability enhancement: Using solubilizers or permeation enhancers to improve skin or alternative delivery system efficiency.
- Stability extension: Incorporation of antioxidants or novel buffers could prolong shelf life or reduce cold chain dependence.
- Injection comfort: Use of less painful excipients like hyaluronic acid or buffering agents that minimize injection site discomfort.
- Alternative formulation types: Exploring sustained-release or micro-needle patches via excipient modification.
Are there commercial opportunities in formulating CETROTIDE with new excipients?
The market favors formulations that improve patient compliance or reduce logistical demands:
- Biocompatible, non-pyrogenic excipients: These can enable pre-filled syringes or auto-injectors, reducing preparation time.
- Ready-to-use formulations: Lyophilized powders with stable excipient matrices facilitate distribution without requiring reconstitution.
- Novel excipient combinations: Patents on new excipient blends can create barriers to entry and qualify for market exclusivity.
Competitive landscape: leading pharmaceutical firms often develop proprietary excipient systems to differentiate their formulations. Patent filings around excipient combinations are increasing, influencing R&D pipelines.
What are the intellectual property considerations?
Patent filings have covered:
- Peptide excipients and stabilizers: Claims around stabilizer combinations that extend shelf life.
- Delivery systems: Autoinjector-compatible formulations with specialized excipients.
- Novel buffers: Use of innovative buffering agents that improve stability or reduce injection pain.
Patent exclusivity typically lasts 10-15 years, supporting commercialization strategies centered around specific excipient formulations.
How can market players leverage excipient strategies for CETROTIDE?
- Formulation innovation: Developing novel excipients can extend patent protection and market share.
- Regulatory pathways: Demonstrating improved stability or patient experience with new excipients may facilitate approval.
- Partnerships: collaborations with excipient suppliers can ensure access to cutting-edge stabilization agents.
- Cost efficiency: Utilizing cost-effective excipients without compromising stability can improve margins.
What are the key regulatory considerations?
Regulatory agencies, such as the FDA and EMA, require detailed documentation demonstrating excipient compatibility, stability, and safety. Changes in excipient composition require supplemental filings, making innovation pathways complex but potentially rewarding.
Summary of commercial opportunities
| Opportunity |
Description |
Strategic Implication |
| Excipient innovation |
Developing new stabilizers or permeation enhancers |
Extends patent life, improves patient experience |
| Alternative delivery systems |
Micro-needles, patches using excipient modifications |
Opens new patient segments, reduces clinician dependence |
| Cost reduction |
Using more economical excipients |
Enhances margins, competitive pricing |
| Regulatory advantage |
Demonstrate stability and bioavailability |
Accelerate approval processes |
Closing: Key Takeaways
- CETROTIDE's formulation relies on excipients ensuring stability, efficacy, and patient comfort.
- Innovation in excipient design offers pathways for extending patent protection and differentiating products.
- Stable, patient-friendly formulations can open new markets, especially with delivery system enhancements.
- Regulatory considerations demand rigorous testing and documentation for any excipient modifications.
- Strategic partnerships with excipient suppliers can facilitate formulation advancements and cost efficiencies.
FAQs
Q1: Are there patent restrictions on excipient use in CETROTIDE formulations?
Yes, patents cover specific excipient combinations and delivery systems, typically lasting 10-15 years from filing date.
Q2: Can excipient modifications impact CETROTIDE's bioavailability?
Yes, changes can improve or impair bioavailability; rigorous testing is required to validate any formulation adjustments.
Q3: What excipients are considered safe for long-term injection use?
Excipients like sodium chloride, buffering agents, and stabilizers with established safety profiles are standard for injectable peptides.
Q4: Are novel excipients permitted in pharmaceutical formulations?
Yes, provided they meet safety, efficacy, and stability criteria and after regulatory approval.
Q5: How does excipient choice influence CETROTIDE's shelf life?
Proper excipients prevent peptide degradation, aggregation, and pH shifts, thus extending shelf stability.
References
- European Medicines Agency. (2020). CETROTIDE Summary of Product Characteristics. EMA.
- U.S. Food and Drug Administration. (2021). Clinical Pharmacology and Biopharmaceutics Data. FDA.
- Patel, R., & Zhang, Y. (2022). Advances in peptide drug formulation: Stabilizers and excipients. Journal of Pharmaceutical Sciences, 111(3), 1123–1134.
- International Council for Harmonisation. (2020). ICH Q3A(R2): Impurities in New Drug Substances. ICH.
- World Health Organization. (2019). Guidelines on stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO.
